대한의생명과학회지 (Biomedical Science Letters)

  • 제28권4호
  • /
  • Pages.229-236
  • /
  • 2022
  • /
  • 1738-3226(pISSN)
  • /
  • 2288-7415(eISSN)
대한의생명과학회 (The Korean Society for Biomedical Laboratory Sciences)
권호 표지
DOI QR코드

DOI QR Code

Analysis of HR-HPV Prevalence among Unvaccinated Busan Women

  • Dong Hyeok, Kim (Department of Clinical Laboratory Science, Catholic University of Pusan) ;
  • Kyung Eun, Lee (Department of Clinical Laboratory Science, Catholic University of Pusan)
  • 투고 : 2022.10.19
  • 심사 : 2022.11.09
  • 발행 : 2022.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

To prevent cervical cancer, human papillomavirus (HPV) bivalent and quadrivalent vaccinations are common, but there is a need for a vaccination system based on the high-risk human papillomavirus (HR-HPV) genotype that differs by region. This study aimed to investigate the prevalence of HPV and the distribution of HR-HPV genotypes in 2,014 women who were not vaccinated against HPV. In this study, HPV DNA testing was performed on 2,014 women not vaccinated against HPV and who visited the Busan Obstetrics and Gynecology Department from September 2020 to July 2021. In addition, liquid-based cytology (LBC) test was performed on 493 cases of HR- HPV genotype infection confirmed by HPV DNA test. The prevalence of HPV among women in Busan was positive in 609 (30.2%) out of 2,014 cases. Among the 609 HPV-positive cases, HR-HPV infection accounted for 493 cases (81.0%), which is a high proportion. Of the total 493 HR-HPV infection cases, liquid-based cytology (LBC) was within normal limits (WNL) in 266 cases (54.0%), atypical squamous cells of undetermined significance (ASCUS) in 97 cases (19.7%), low-grade squamous intraepithelial lesion (LGSIL) in 88 cases (17.8%), and high-grade squamous intraepithelial lesion (HGSIL) in 42 cases (8.5%). Single HR-HPV 52 and 16 accounted for the highest and second highest infection rates, respectively. The high infection rate among women aged 18~39 underscores the need for continuous monitoring. In addition, when there were abnormal findings in the cervical epithelium, HPV 52 was the most common, while in the case of HGSIL, HPV 16 was the most common. The HR-HPV genotypes related to cervical cancer should be continuously collected and monitored for use in health policies, including local and national vaccinations.

키워드

과제정보

This research was funded by the National Research Foundation of Korea. The grant was funded by the Korean Government, grant number NRF-2020R1A2C1102228.

참고문헌

  1. Aro K, Nieminen P, Louvanto K, Jakobsson M, Virtanen S, Lehtinen M, Dillner J, Kalliala I. Age-specific hpv type distribution in high-grade cervical disease in screened and unvaccinated women. Gynecol Oncol. 2019. 154: 354-359. https://doi.org/10.1016/j.ygyno.2019.05.024
  2. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003. 16: 1-17.
  3. Castle PE. Beyond human papillomavirus: The cervix, exogenous secondary factors, and the development of cervical precancer and cancer. J Low Genit Tract Dis. 2004. 8: 224-230. https://doi.org/10.1097/00128360-200407000-00011
  4. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S. Worldwide distribution of human papillomavirus types in cytologically normal women in the international agency for research on cancer hpv prevalence surveys: A pooled analysis. Lancet. 2005. 366: 991-998. https://doi.org/10.1016/S0140-6736(05)67069-9
  5. Cubie HA. Diseases associated with human papillomavirus infection. Virology. 2013. 445: 21-34. https://doi.org/10.1016/j.virol.2013.06.007
  6. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis. Lancet Infect Dis. 2007. 7: 453-459. https://doi.org/10.1016/S1473-3099(07)70158-5
  7. Drolet M, Benard E, Perez N, Brisson M, Ali H, Boily MC, Baldo V, Brassard P, Brotherton JML, Callander D, Checchi M, Chow EPF, Cocchio S, Dalianis T, Deeks SL, Dehlendorff C, Donovan B, Fairley CK, Flagg EW, Gargano JW, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: Updated systematic review and meta-analysis. The Lancet. 2019. 394: 497-509. https://doi.org/10.1016/s0140-6736(19)30298-3
  8. Hong S, Won YJ, Lee JJ, Jung KW, Kong HJ, Im JS, Seo HG. Cancer statistics in korea: Incidence, mortality, survival, and prevalence in 2018. Cancer Res Treat. 2021. 53: 301-315. https://doi.org/10.4143/crt.2021.291
  9. Kim MA, Han GH, Kim JH, Seo K. Current status of human papillomavirus infection and introduction of vaccination to the national immunization program in korea: An overview. J Korean Med Sci. 2018. 33: e331.
  10. Kind AB, Pavelyev A, Kothari S, El Mouaddin N, Schmidt A, Morais E, Guggisberg P, Lienert F. Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent hpv vaccine within a gender-neutral vaccination programme in switzerland. BMC Public Health. 2020. 20: 671.
  11. Krashias G, Koptides D, Christodoulou C. Hpv prevalence and type distribution in cypriot women with cervical cytological abnormalities. BMC Infect Dis. 2017. 17: 346.
  12. Long W, Yang Z, Li X, Chen M, Liu J, Zhang Y, Sun X. Hpv-16, hpv-58, and hpv-33 are the most carcinogenic hpv genotypes in southwestern china and their viral loads are associated with severity of premalignant lesions in the cervix. Virol J. 2018. 15: 94.
  13. Ma DM, Sun MX, Li XY, Li S, Nie XJ, Jin DH, Chen LM. Distribution of high-risk human papillomavirus genotypes in male attendees at a clinic for sexually transmitted infections in northern china. Eur Rev Med Pharmacol Sci. 2019. 23: 9714-9720.
  14. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: A systematic review and meta-analysis. Lancet Infect Dis. 2012. 12: 781-789. https://doi.org/10.1016/S1473-3099(12)70187-1
  15. Martins TR, Mendes de Oliveira C, Rosa LR, de Campos Centrone C, Rodrigues CL, Villa LL, Levi JE. Hpv genotype distribution in brazilian women with and without cervical lesions: Correlation to cytological data. Virol J. 2016. 13: 138.
  16. Min KJ, Kwon SH, Kim S, Kim HJ, Seong SJ, Song YJ, Shin JW, Lee KH, Lim MC, Chung HH, Ju W, Hong JH, Lee JW, Kim JW, Bae DS, Lee JK. Preventive vaccination against cervical cancer: Korean society of gynecologic oncology guideline. J Gynecol Oncol. 2016. 27: e30.
  17. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003. 348: 518-527. https://doi.org/10.1056/NEJMoa021641
  18. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000. 151: 1158-1171. https://doi.org/10.1093/oxfordjournals.aje.a010166
  19. Park E, Kim JY, Choi S, Kim DS, Oh YL. Carcinogenic risk of human papillomavirus (hpv) genotypes and potential effects of hpv vaccines in korea. Sci Rep. 2019. 9: 12556.
  20. Paz-Zulueta M, Alvarez-Paredes L, Rodriguez Diaz JC, Paras-Bravo P, Andrada Becerra ME, Rodriguez Ingelmo JM, Ruiz Garcia MM, Portilla J, Santibanez M. Prevalence of high-risk hpv genotypes, categorised by their quadrivalent and ninevalent hpv vaccination coverage, and the genotype association with high-grade lesions. BMC Cancer. 2018. 18: 112.
  21. Printz C. Fda approves gardasil 9 for more types of hpv. Cancer. 2015. 121: 1156-1157. https://doi.org/10.1002/cncr.29374
  22. Sabol I, Milutin Gasperov N, Matovina M, Bozinovic K, Grubisic G, Fistonic I, Belci D, Alemany L, Dzebro S, Dominis M, Sekerija M, Tous S, de Sanjose S, Grce M. Cervical hpv type-specific pre-vaccination prevalence and age distribution in croatia. PLoS One. 2017. 12: e0180480.
  23. Sasagawa T, Basha W, Yamazaki H, Inoue M. High-risk and multiple human papillomavirus infections associated with cervical abnormalities in japanese women. Cancer Epidemiol Biomarkers Prev. 2001. 10: 45-52.
  24. Topazian HM, Kundu D, Peebles K, Ramos S, Morgan K, Kim CJ, Richter KL, Brewer NT, Peris M, Smith JS. Hpv vaccination recommendation practices among adolescent health care providers in 5 countries. J Pediatr Adolesc Gynecol. 2018. 31: 575-582.e572. https://doi.org/10.1016/j.jpag.2018.06.010
  25. Tran KN, Park Y, Kim BW, Oh JK, Ki M. Incidence and mortality of cervical cancer in vietnam and korea (1999-2017). Epidemiol Health. 2020. 42: e2020075.
  26. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999. 189: 12-19. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
  27. WHO. Human papillomavirus vaccines: Who position paper, october 2014. Wkly Epidemiol Rec. 2014. 89: 465-491.
  28. Won S, Kim MK, Seong SJ. Clinical management of abnormal pap tests: Differences between us and korean guidelines. J Pathol Transl Med. 2020. 54: 213-219. https://doi.org/10.4132/jptm.2020.03.11